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definitive RT/CT. Further treatment intensification for 
patients with relative SUV >0.57 seems justified.  
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Purpose/Objective: 
Introduction: In literature a lower survival in a larger GTV 
was found in a retrospective analysis of a prospective 
database of 270 patients (Dehing-Oberije). These patients 
were treated with (chemo) radiotherapy for NSCLC. This 
raises the question to specify the GTV and the PTV further 
with a cutoff point in our own database with patients treated 
with CCRT for locally advanced NSCLC. 
Purpose: Is the GTV a better predictor of outcome of 
treatment (LC, LRC, DFS, OS) than the PTV? Can we find a 
cut-off with the inclusion of the volume prediction (GTV or 
PTV) to use the least toxic treatment with the same or better 
result for patients with locally advanced non-small cell lung 
carcinoma (NSCLC)? 
Materials and Methods: In 132 patients (PET-CT staged) 
treated with CCRT for locally advanced non-small cell lung 
carcinoma in the period 2005-2012, one observer delineated 
the GTV of the primary tumor and lymph nodes and the 
volume (cc) was calculated. The planning target volume 
(PTV) was generated, prognostic factors and outcome 
registered retrospectively. The Cox regression model and 
multivariate support will be calculated and the difference 
will be tested. The median volume (GTV and PTV) cutoff 
applied and tested separately for consistency in the spline 
predict model. 
Results: In the univariate analysis GTV (>77 cc) (p=0,031/HR 
1.9), PTV (>390 cc) (p=0.0035/HR 2,4) and gender 
(p<0,001/HR 0.3) are significantly favorable prognostic 
factors for overall survival (OS). In the multivariate cox-
regression analysis PTV >390 cc (p=0.012/HR 2,5) and gender 
(p=0,006/HR 0.35) (male: female) but not GTV are 
significantly favorable prognostic factors for OS. Age is in the 
univariate analysis (p=0.018/HR 0.96) and multivariate 
analysis (p=0.01/HR 0.95) the only significantly favorable 
prognostic factor for local relapse free survival.  
Conclusions: The GTV does not have a better prognostic 
value for overall survival and local recurrence free survival in 
patients with locally advanced NSCLC treated with CCRT than 
the PTV (Correlation factor =0.94). 
A cut off point for overall survival was found for GTV 77 cc 
and PTV 390 cc.  
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Purpose/Objective: When formulating radiation treatment 
plans, it has long been assumed that tumor doses should be 
kept homogeneous throughout the tumor in order to 
maximize the likelihood of tumor control. This has lead to 
the widespread adoption of 'D95' as the standard plan-quality 
metric. However, the optimization of this parameter is often 
achieved at the expense of competing dose-volume metrics, 
putting the patient at increased risk of normal tissue 
toxicities despite scant clinical data to support the need for 
dose homogeneity, and mounting biological evidence against 
it. With this in mind, we set out to derive a novel, 
mechanistically-derived metric which accurately derives 
tumor control probabilities from each patient's unique dose 
distributions and fractionation schedules: 'generalized tumor 
dose' (gTD). 
Materials and Methods: The gTD metric was inspired by 
Niemierko's concept of gEUD, which applies a generalized-
mean term ('a') to the dose distribution over the structure of 
interest. Here we apply the same concept, however 
incorporating it into a dose-effect model mechanistically 
derived from known tumor radiobiology, and accounting for 
each patient's unique dosing, fractionation schedule, and 
tumor characteristics. In effect, the derived gTD metric 
reflects the level of absolute cell survival within the tumor, 
subject to the 'a'-based relative weighting of the high or low 
end of the dose distribution. Using parameter optimization 
methods on clinical lung tumor data from two institutional 
cohorts (NKI: N=266 & WUSTL: N=50), we tested the current 
assumption that outcome (local control/failure at last 
followup) is determined by the sum of independent dose 
effects to tumor sub-volumes. 
Results: 
 
Fitting model parameters to the combined cohort data using 
both log-likelihood and actuarial methods, we were able to 
